References chapter 29 Behçet syndrome - EULAR

1 EULAR Textbook on Rheumatic Diseases References chapter 29 Beh et syndrome Direskeneli H. Autoimmunity vs autoinflammation in Beh et s disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 2006;45:1461 5 Espinosa G, Font J, Tassies D, et al. Vascular involvement in Beh et s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002;112:37 43. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Beh et syndrome . Am J Med 2004;117:867 70. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Beh et s syndrome : effects on long-term prognosis. Arthritis Rheum 1997;40:769 74. Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Beh et disease: review of the literature. Semin Arthritis Rheum 2004;33:320 35. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Beh et syndrome : a 2-decade outcome survey of 387 patients followed at a dedicated center.

2 Medicine (Baltimore) 2003;82:60 76. Yazici H, Fresko I, Yurdakul S. Beh et s syndrome : disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007;3:148 55. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet s syndrome . N Engl J Med. 1990;322:281 5. Remmers EF, Cosan F, Kirino Y et al. Genome wide association studies identifies variants in the MHC Class I, IL 10, and IL23R-IL12RB2 regions associated with Behcet s disease. Nat Genet 2010:42:698-702 Mizuki N, Meguro A, Ota M et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh et's disease susceptibility loci. Nat Genet. 2010; 42(8):703-6. Akman-Demir G, Saip S, Siva A. Beh et s disease. Curr Treat Options Neurol 2011;13(3):290-310. Ideguchi H, Suda A, Takeno M et al. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore) 2011;90(2):125-132. Relapsing polychondritis Buckley LM, Ades PA.

3 Progressive aortic valve inflammation occurring despite apparent remission of relapsing polychondritis. Arthritis Rheum 1992;35:812 14. EULAR Textbook on Rheumatic Diseases Chang-Miller A, Okamura M, Torres VE, et al. Renal involvement in relapsing polychondritis. Medicine 1987;66:202 17. Frances C, el Rassi R, Laporte JL, et al. Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center. Medicine (Baltimore) 2001;80:173 9. Hanslik T, Wechsler B, Piette J-C, et al. Central nervous system involvement in relapsing polychondritis. Clin Exp Rheumatol 1994;12:539 41. Kent PD, Michet CJ Jr, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol 2004;16:56 61. McAdam LP, O Hanlan MA, Bluestone R, et al. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine 1976;55:193 215. Mpofu S, Estrach C, Curtis J, et al. Treatment of respiratory complications in recalcitrant relapsing polychondritis with infliximab.

4 Rheumatology (Oxford) 2003;42:1117 8. Saadoun D, Deslandre CJ, Allanore Y, et al. Sustained response to infliximab in 2 patients with refractory relapsing polychondritis. J Rheumatol 2003;30:1394 5. Sundaram MBM, Rajput AH. Nervous system complications of relapsing polychondritis. Neurology 1983;33:513 15. Zeuner M, Straub RH, Rauh G, et al. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol 1997;24:96 101. Eye involvement Harper SL, Foster CS. The ocular manifestations of rheumatoid disease. Int Ophthalmol Clin 1998;38:1 9. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondylarthropathy. Arch Ophthalmol 1997;115:61 4. Marmor ME, Carr RE, Easterbrook M, et al. American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology.

5 Ophthalmology 2002;109:1377 82. Patel SJ, Lundy DC. Ocular manifestations of autoimmune disease. Am Fam Physician 2002;66:991 8. Perez VL, Chavala SH, Ahmed M, et al. Ocular manifestations and concepts of systemic vasculitides. Surv Ophthalmol 2004;49:399 418. Rucker CW, Ferguson RH. Ocular manifestations of relapsing polychondritis. Arch Ophthalmol 1965;73:46 50. Soo MP, Chow SK, Tan CT, et al. The spectrum of eye involvement in patients with systemic lupus erythematodes without ocular symptoms. Lupus 2000;9:511 4. EULAR Textbook on Rheumatic Diseases Zierhut M, St biger N, Deuter CME, et al. Beh et s disease. In: Pleyer U, Mondino B, eds. Essentials in ophthalmology: uveitis and immunological disorders. Berlin, Heidelberg: Springer, 2005:173 200. New References in text (Behcet and Relapsing Polychondritis): 1) Mahr A, Belarbi L, Wechler B et al. Population-based prevalence study of Beh et's disease:differences by ethnic origin and low variation by age at immigration.

6 Arthritis Rheum 2008:58:3951-3959. 2) Seyahi E, Tahir Turanl E, Mangan MS et al. The prevalence of Beh et s syndrome , familial Mediterranean fever, HLA-B51 and MEVF gene mutations among ethnic Armenians living in Istanbul, Turkey. Clin Exp Rheumatol 2010; 28(4 suppl 60): S67-75. 3) Ugurlu S, Seyahi E, Yazici H. Prevalence of angina, myocardial infarction and intermittent claudication assessed by Rose Questionnaire among patients with Behcet's syndrome . Rheumatology (Oxford). 2008;47:472-5. 4) Cheon JH, Celik AF, Ho Kim W. Behcet s disease: Gastrointestinal involvement. Behcet s syndrome , eds Yazici Y and Yazici H, Springer, 2010:165-188. 5) Fresko I, Soy M, Hamuryudan V et al. Genetic anticipation in Behcet s syndrome . Ann Rheum Dis 1998:57:45-48. 6) de Menthon M, Lavalley MP, Maldini C et al. HLA-B51/B5 and the risk of Beh et's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009:61:1287-1296.

7 7) Remmers EF, Cosan F, Kirino Y et al. Genome wide association studies identifies variants in the MHC Class I, IL 10, and IL23R-IL12RB2 regions associated with Behcet s disease. Nat Genet 2010:42:698-702. 8) Saruhan-Direskeneli G, Uyar FA, Cefle A et al. Expression of KIR and C-type lectin receptors in Behcet's disease. Rheumatology (Oxford) 2004:43:423-427. 9) Mizuki N, Meguro A, Tohnai I et al. Association of Major Histocompatibility Complex Class I Chain-Related Gene A and HLA-B Alleles with Beh et's Disease in Turkey. Jpn J Ophthalmol 2007:51:431-436. 10) Gul A, Ohno S. Genetics of Behcet s disease. Behcet s syndrome , eds Yazici Y and Yazici H, Springer, 2010:265-276. 11) Frassanito MA, Dammacco R, Cafforio P et al. Th1 polarization of the immune response in Beh et's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999:42:1967-1974. 12) Imamura Y, Kurokawa MS, Yoshikawa H et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease.

8 Clin Exp Immunol 2005:139:371-378. 13) Hamzaoui K, Hamzaoui A, Guemira F et al. Cytokine profile in Beh et's disease patients. Relationship with disease activity. Scand J Rheumatol. 2002:31:205-210. 14) Neves FS, Carrasco S, Goldenstein-Schainberg C et al. Neutrophil hyperchemotaxis in Beh et's disease: a possible role for monocytes orchestrating bacterial-induced innate immune responses. Clin Rheumatol. 2009:28:1403-1410. 15) Freysdottir J, Hussain L, Farmer et al. Diversity of gammadelta T cells in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis. 2006;12:271-277. 16) Hatemi G, Fresko I, Tascilar K et al. Increased enthesopathy among Beh et's syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum. 2008;58:1539-45. 17) Kaburaki T, Araki F, Takamoto M et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Beh et's disease.

9 Graefes Arch Clin Exp Ophthalmol. 2010;248:709-714. EULAR Textbook on Rheumatic Diseases 18) Hatemi G, Silman A, Bang D et al. EULAR recommendations for the management of Beh et disease. Ann Rheum Dis. 2008;67:1656-1662. 19) Lahmer T, Treiber M, von Werder A et al. Relapsing polychondritis: An autoimmune disease with many faces. Autoimmun Rev. 2010;9:540-6. 20) Genevois O, Calenda E, Nasser Hypopyon uveitis (without scleritis) a manifestation symptom of relapsing polychondritis. Ann Ophthalmol (Skokie). 2009;41:208-1. 21) Carter JD. Treatment of relapsing polychondritis with a TNF antagonist. J Rheumatol. 2005;32:1413. 22) Seymour MW, Home DM, Williams RO Prolonged response to anti-tumour necrosis factor treatment with adalimumab (Humira) in relapsing polychondritis complicated by aortitis. Rheumatology (Oxford). 2007;46:1738-1739. 23) Leroux G, Costedoat-Chalumeau N, Brihaye B. Treatment of relapsing polychondritis with rituximab: a retrospective study of nine patients.

10 Arthritis Rheum. 2009;61:577-82. 24) Sachetto Z, Mahayri N, Ferraz RH et al. Beh et s disease in Brazilian patients: demographic and clinical features. Rheumatol Int 2011 Apr 2011 (Epub ahead of print) 25) Cho SB, Cho S, Lee JH et al. Eryjthema nodosum like skin lesions associated with Beh et s disease show 18F-fluorodeoxyglucose uptake on PET/CT. Clin Exp Rheumatol 2011 (Epub ahead of print) 26) Togashi A, Saito S, Kaneko F et al. Skin-prick test with self-saliva in patients with oral apthoses: a diagnostic pathergy with Beh et s disease and recurrent apthosis. Inflamm Allergy Drug Targets 2011:10(3):164-170. 27) Albayram S, Saip S, Hasiloglu ZI et al. Evaluation of parenchymal neuro-beh et disease by using susceptibility weighted imaging. AJNR Am J Neuroradiol 2011;32(6):1050-1055. 28) Shin SJ, Lee SK, Kim TI et al. Chronological changes in the systemic manifestations of intestinal Beh et s disease and their significance in diagnosis.